Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Phase 2 Completed
55 enrolled 10 charts
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
Phase 2 Completed
30 enrolled 16 charts
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
Phase 2 Completed
16 enrolled 7 charts
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase 2 Completed
55 enrolled 8 charts
Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
Phase 2 Completed
40 enrolled 9 charts
MAESTRO HN
Phase 2 Completed
86 enrolled 11 charts
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2 Completed
21 enrolled 10 charts
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Phase 1 Completed
43 enrolled
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
Phase 2 Completed
6 enrolled
Immunotoxin Therapy in Treating Patients With Advanced Cancer
Phase 1 Completed
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
Phase 1 Completed
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase 2 Completed
30 enrolled
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2 Completed
15 enrolled 8 charts
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
Phase 1/2 Completed
66 enrolled
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Phase 2 Completed
11 enrolled 7 charts
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
Phase 1/2 Completed
45 enrolled
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Phase 1 Completed
41 enrolled
Radiation Therapy in Treating Patients With Head and Neck Cancer
Phase 3 Completed
460 enrolled
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
Phase 2 Completed
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2 Completed
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
Phase 1 Completed
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1 Completed
30 enrolled
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Phase 1 Completed
15 enrolled
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
Phase 2 Completed
144 enrolled
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
24 enrolled
BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase 1/2 Completed
27 enrolled
Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
Phase 1 Completed
39 enrolled
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
48 enrolled
Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck
Phase 2 Completed
37 enrolled
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase 1 Completed
75 enrolled
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
Phase NA Completed
40 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
Phase 1/2 Completed
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
Phase 2 Completed
45 enrolled
PET Scans in Patients With Head And Neck Cancer Who Are Undergoing 3-Dimensional Conformal Radiation Therapy And Intensity-Modulated Radiation Therapy
Phase NA Completed
40 enrolled